Evidence map›Paper›PMID 39971377›Full record

ReviewAnnual review of biomedical engineering2025

Therapeutic Ultrasound for Multimodal Cancer Treatment: A Spotlight on Breast Cancer.

Zehra E F Demir, Natasha D Sheybani

Abstract readReview
In one paragraph

Review in Annual review of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zehra E F DemirDepartment of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA; email: qkh9uu@virginia.edu, nds3sa@virginia.edu.
Natasha D SheybaniDepartment of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA; email: qkh9uu@virginia.edu, nds3sa@virginia.edu.

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Immunoengineering Next-Generation Cancer Therapies with Focused UltrasoundDP5OD031846 · OD · UNIVERSITY OF VIRGINIA · PI SHEYBANI, NATASHA DIBA · 2021 to 2025
$2.0M
NCI NIH HHS T32 CA009109NIH HHS DP5 OD031846
6 · The paper itself

Abstract

Cancer remains a leading cause of mortality worldwide, and the demand for improved efficacy, precision, and safety of management options has never been greater. Focused ultrasound (FUS) is a rapidly emerging strategy for nonionizing, noninvasive intervention that holds promise for the multimodal treatment of solid cancers. Owing to its versatile array of bioeffects, this technology is now being evaluated across preclinical and clinical oncology trials for tumor ablation, therapeutic delivery, radiosensitization, sonodynamic therapy, and enhancement of tumor-specific immune responses. Given the breadth of this burgeoning domain, this review places a spotlight on recent advancements in breast cancer care to exemplify the multifaceted role of FUS technology for oncology indications-outlining physical principles of FUS-mediated thermal and mechanical bioeffects, giving an overview of results from recent preclinical and clinical studies investigating FUS with and without adjunct therapeutics in primary or disseminated breast cancer settings, and offering perspectives on the future of the field.

Indexed as

Breast NeoplasmsUltrasonic TherapyAnimalsCombined Modality TherapyFemaleHigh-Intensity Focused Ultrasound AblationHumansbreast cancercancer immunotherapydrug deliveryfocused ultrasoundHIFUimage-guided therapymetastasis

Identifiers

PMID39971377
PMCPMC12411100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.